Esperion Therapeutics Inc (NASDAQ: ESPR) on Friday, soared 0.95% from the previous trading day, before settling in for the closing price of $2.10. Within the past 52 weeks, ESPR’s price has moved between $1.04 and $3.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 7.64% over the last five years. The company achieved an average annual earnings per share of 84.83%. With a float of $194.99 million, this company’s outstanding shares have now reached $197.03 million.
The firm has a total of 240 workers. Let’s measure their productivity. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc is 1.04%, while institutional ownership is 65.81%. The most recent insider transaction that took place on Oct 17 ’24, was worth 227. In this transaction Chief Commercial Officer of this company sold 107 shares at a rate of $2.12, taking the stock ownership to the 162,552 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Officer proposed sale 107 for $2.12, making the entire transaction worth $227.
Esperion Therapeutics Inc (ESPR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 84.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 1.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach 0.32 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Analysing the last 5-days average volume posted by the [Esperion Therapeutics Inc, ESPR], we can find that recorded value of 6.7 million was better than the volume posted last year of 6.18 million. As of the previous 9 days, the stock’s Stochastic %D was 38.36%. Additionally, its Average True Range was 0.16.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 45.38%, which indicates a significant increase from 34.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.70% in the past 14 days, which was higher than the 68.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.97, while its 200-day Moving Average is $2.22. Now, the first resistance to watch is $2.17. This is followed by the second major resistance level at $2.23. The third major resistance level sits at $2.30. If the price goes on to break the first support level at $2.04, it is likely to go to the next support level at $1.97. Now, if the price goes above the second support level, the third support stands at $1.91.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 421.69 million based on 197,035K outstanding shares. Right now, sales total 116,330 K and income totals -209,250 K. The company made 51,630 K in profit during its latest quarter, and -29,520 K in sales during its previous quarter.
